Form Type:  CT ORDER
Filing Date:  4/17/2012 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.00 (0.00%)  
Trade Time: 
Jan 19  
Market Cap: 
Trade CTIC now with

© 2018  
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis. PIXUVRI PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. In May 2012, the European Commission granted conditional marketing authorization in the E.
Register and access this filing in: